Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
FHTX Stock Chart & Stats
$6.02
$0.09(1.92%)
At close: 4:00 PM EST
$6.02
$0.09(1.92%)
Day’s Range― - ―
52-Week Range$2.94 - $6.95
Previous CloseN/A
Volume24.60K
Average Volume (3M)157.41K
Market Cap
$352.66M
Enterprise Value$285.86M
Total Cash (Recent Filing)$180.28M
Total Debt (Recent Filing)$22.53M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Mar 05, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding58,581,604
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-5.69
Price to Sales (P/S)11.46
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue11.66
Enterprise Value/Gross Profit79.05
Enterprise Value/Ebitda-3.69
Forecast
1Y Price Target
$11.38Price Target Upside89.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial RunwayCash runway into 2028 provides financial stability to support ongoing trials and preclinical programs without immediate need for new capital.
Preclinical Safety And DifferentiationSelective CBP and EP300 degraders demonstrated anti-tumor activity in preclinical models without platelet or megakaryocyte toxicity, supporting potential combination strategies and clinical differentiation.
Strategic PartnershipStrategic collaboration with Eli Lilly shares development costs and expertise for FHD-909, reducing financial burden and increasing the likelihood of successful clinical advancement.
Bears Say
Management TurnoverCFO resignation creates execution and planning risk during a critical development phase and may generate short-term uncertainty around financial management.
Partner Decision DependencyAdvancement of FHD-909 depends on Lilly's development decision, creating dependency risk that could delay trial progression or constrain strategic options.
Research Objectivity RiskDisclosure of a potential conflict of interest in analyst reports may undermine investor confidence and reduce perceived objectivity of research coverage on the company.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $2.94 and its highest was $6.95 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $352.66M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 46 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.083.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 58,581,604 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went up 13.314%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Foghorn Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.38 (89.04% Upside)
$11.38 (89.04% Upside)
Hedge Fund Trend
Increased
By 108.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.15%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$11.38
▲(89.04% Upside)
Technical Analysis
Tonix Pharma
―
Astria Therapeutics
―
Monte Rosa Therapeutics
―
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.11% Insiders
9.37% Mutual Funds
43.29% Other Institutional Investors
40.92% Public Companies and
Individual Investors